Revolution Medicines, Inc. $RVMD is Catalyst Funds Management Pty Ltd’s 4th Largest Position

Catalyst Funds Management Pty Ltd grew its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 6.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 223,569 shares of the company’s stock after buying an additional 13,400 shares during the quarter. Revolution Medicines accounts for 4.1% of Catalyst Funds Management Pty Ltd’s investment portfolio, making the stock its 4th largest holding. Catalyst Funds Management Pty Ltd’s holdings in Revolution Medicines were worth $17,807,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Revolution Medicines by 6.7% in the 4th quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock valued at $1,331,739,000 after purchasing an additional 1,056,792 shares in the last quarter. Farallon Capital Management LLC increased its holdings in shares of Revolution Medicines by 2.1% in the 3rd quarter. Farallon Capital Management LLC now owns 14,625,692 shares of the company’s stock valued at $683,020,000 after purchasing an additional 300,000 shares in the last quarter. Baker BROS. Advisors LP increased its holdings in shares of Revolution Medicines by 1.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 9,455,357 shares of the company’s stock valued at $441,565,000 after purchasing an additional 90,385 shares in the last quarter. Nextech Invest Ltd. increased its holdings in shares of Revolution Medicines by 20.7% in the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after purchasing an additional 1,304,347 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP increased its holdings in shares of Revolution Medicines by 2.1% in the 3rd quarter. Paradigm Biocapital Advisors LP now owns 6,223,291 shares of the company’s stock valued at $290,628,000 after purchasing an additional 130,000 shares in the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on RVMD. Evercore reiterated an “outperform” rating on shares of Revolution Medicines in a report on Tuesday, April 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a report on Tuesday, April 21st. Wedbush increased their price target on shares of Revolution Medicines to $165.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Stifel Nicolaus reiterated a “buy” rating on shares of Revolution Medicines in a report on Monday, April 20th. Finally, Guggenheim increased their price target on shares of Revolution Medicines to $205.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $111.35.

Insider Activity

In other Revolution Medicines news, COO Margaret A. Horn sold 4,583 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $455,916.84. Following the completion of the transaction, the chief operating officer directly owned 157,570 shares in the company, valued at approximately $15,675,063.60. This trade represents a 2.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Jack Anders sold 2,753 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $273,868.44. Following the transaction, the chief financial officer owned 125,512 shares of the company’s stock, valued at $12,485,933.76. This trade represents a 2.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 184,592 shares of company stock worth $24,499,532 in the last three months. Company insiders own 8.20% of the company’s stock.

Revolution Medicines Stock Performance

NASDAQ:RVMD opened at $151.56 on Friday. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.19. The firm has a 50-day moving average price of $123.75 and a two-hundred day moving average price of $101.21. Revolution Medicines, Inc. has a twelve month low of $34.00 and a twelve month high of $156.25. The company has a market capitalization of $32.22 billion, a P/E ratio of -21.44 and a beta of 1.41.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same quarter in the previous year, the firm posted ($1.13) EPS. As a group, research analysts expect that Revolution Medicines, Inc. will post -7.75 earnings per share for the current fiscal year.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.